Africa & Middle East

Avéli® stands out as the first and only U.S. FDA-cleared device designed to identify and precisely release the fibrous septae responsible for cellulite dimpling.

This partnership marks a major step in advancing clinical excellence, operational efficiency, and innovation in one of the Middle East’s most rapidly evolving medical markets.

The newly constructed, purpose-built facility is designed to handle high potency drugs, including oncology and hormone products.

The biotechnology market was valued at USD 1.6 trillion in 2020 and is expected to grow at a compound annual growth rate of 14.2%, reaching USD 4.05 trillion by 2035.

These landmark achievements highlight AMCE’s growing capability to deliver complex, life-saving procedures within Africa, reducing the long-standing need for patients to travel abroad for advanced medical treatments.

This new alliance stands out as a bold and unconventional initiative that blends healthcare innovation with creative design thinking.

The innovative test measures a biological feature known as “calories to satiation” (CTS), which refers to the amount of food a person needs to feel full.

The collaboration reinforces Bupa CareConnect’s leadership in the Kingdom’s digital healthcare transformation and aligns with the national objectives of Saudi Vision 2030.

Amana Healthcare Bahrain was established through a strategic partnership with Bahrain Mumtalakat Holding Company (Mumtalakat), the Kingdom’s sovereign wealth fund.

The launch ceremony took place at the John F. Kennedy Medical Center in Monrovia and brought together a wide representation of health professionals from both public and private institutions.